Travere Therapeutics (TVTX)
NASDAQ:TVTX
Want to see TVTX full AI Analyst Report?
Earnings Data
Report Date
Jul 30, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.05Last Year’s EPS
-0.14Same Quarter Last Year
Strong Buy
Based on 13 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed a strongly positive commercial and clinical momentum: a landmark FDA approval in FSGS, record demand and an 88% YoY increase in FILSPARI sales, encouraging pipeline progress (HARMONY restart with 2027 readout expectation), and improved non-GAAP profitability. Offsetting these positives are significant near-term cost increases (R&D and SG&A), higher royalty expense due to accounting changes, a continuing GAAP net loss, and some short-term revenue recognition/timing headwinds and education needs with physicians and payers. Overall, the positives (major approval, large sales growth, record demand, and clear runway to advance the pipeline) outweigh the near-term financial and operational challenges.Company Guidance
First FDA Approval in FSGS — Major Commercial Milestone
FILSPARI received full FDA approval for FSGS (April 13), becoming the first and only approved medicine for this rare disease; company estimates >30,000 U.S. patients currently eligible in FSGS and >100,000 total U.S. patients eligible across IgA nephropathy and FSGS, supporting a modeled ~$3 billion potential peak sales opportunity.
Strong FILSPARI Commercial Performance
Record commercial demand with 993 new patient start forms in Q1 and U.S. FILSPARI net product sales of $105.2 million, an ~88% year-over-year increase despite typical Q1 insurance resets, gross-to-net dynamics, and fewer revenue shipping weeks.
Robust Company Revenue and Product Mix
Total U.S. net product sales were $124.5 million and total revenue was $127.2 million in Q1 2026; Thiola/Thiola EC contributed $19.3 million and licensing/collaboration revenue was $2.7 million.
Profitability Improvement on a Non-GAAP Basis
On a non-GAAP adjusted basis the company reported net income of $4.1 million, or $0.05 per share, versus a non-GAAP net loss of $16.9 million (−$0.19) in Q1 2025 — a material improvement in underlying profitability.
Pipeline Progress — HARMONY Phase III Restarted
Dosed the first new patient in the pivotal Phase III HARMONY study of pegtibatinase for classical homocystinuria after enrollment restart; top-line HARMONY results are expected in 2027 and the program targets an estimated 7,000–10,000 addressable HCU patients globally.
Supportive Clinical and Real-World Evidence
New publications and data (CJASN, PROTECT) reinforce FILSPARI’s efficacy: PROTECT showed patients reaching proteinuria <0.3 g/g had eGFR decline <1 mL/min/yr; DUPLEX data showed sustained proteinuria reductions to ~1.5 g/g and CJASN publication demonstrated consistent efficacy/safety in genetic FSGS. These data support strong physician adoption and persistence.
Solid Balance Sheet and Milestone Receipt
As of March 31, 2026 the company reported cash, cash equivalents, marketable securities and receivables of ~ $352 million (cash balance reported ~$264.7M with a $25M Mirum milestone received in April), supporting near-term operations and pipeline investment.
TVTX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
TVTX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 04, 2026 | $44.91 | $44.80 | -0.24% |
Feb 19, 2026 | $29.30 | $30.39 | +3.72% |
Oct 30, 2025 | $29.65 | $35.16 | +18.58% |
Aug 06, 2025 | $17.24 | $16.91 | -1.91% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Travere Therapeutics (TVTX) report earnings?
Travere Therapeutics (TVTX) is schdueled to report earning on Jul 30, 2026, After Close (Confirmed).
What is Travere Therapeutics (TVTX) earnings time?
Travere Therapeutics (TVTX) earnings time is at Jul 30, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TVTX EPS forecast?
TVTX EPS forecast for the fiscal quarter 2026 (Q2) is -0.05.